A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

NCT03322631 · Completed

Last updated 2026-05-28

This clinical trial tests the safety of the medication tirzepatide in Japanese adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 48 people

Who can join Ages 20–70 · all sexes

Timeline Started 2017-11 · est. completion 2018-11

Where 2 sites · Japan

What this study is testing ClinicalTrials.gov NCT03322631 ↗

Description as written by the study sponsor.

The purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to remove it. * How tirzepatide affects the levels of blood sugar. This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC.
Placebo Drug

Administered SC.

Main thing measured	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03322631 ↗